Filter Results
Filter Results
Allogeneic Autologous Bioconjugates/ADC Exosomes Expression Technologies iPSCs Mammalian Microbial mRNA Parenteral Drug Product Small Molecules Viral Vectors
Antibody Drug Conjugates Bioavailability Enhancement Bispecific Antibody Difficult to Express Proteins Drug device combinations Drug Substance (API/HPAPI) Enhanced ADCC Fabs, Fusion, Scaffold and other Recombinant Proteins Inhalation Injectables Lipid Nanoparticle Encapsulation Monoclonal Antibody Oral Drug Products Particle Engineering Solid Form Services
Analytical Development Antibody Humanization & Deimmunization API Services Bispecific DNA-to-IND Cell Line Development Clinical Supply Services Commercial Supply Services Early De-risking & Optimization Fabs and Fc-Fusion proteins DNA-to-IND First-in-Human Services Formulation Development and Optimization Ibex® Dedicate Immunogenicity Assessment IND-to-BLA mAb DNA-to-IND Manufacturing: cGMP Manufacturing: GMP Drug Product Manufacturing: GMP Drug Substance Manufacturing: Non-GMP Manufacture Parenteral Drug Product Development PBPK Modeling Process Development and Optimization Regulatory Services Scaffolds and Other Recombinant Proteins DNA-to-IND Solid Form Services Special Analytical Services Strain Development Tech Transfer Tissue Acquisition Viral Vector Expression Technologies
4D-Nucleofector LV bYlok™ Bispecific Antibodies Technology GS Discovery® GS Effex® GS Gene Expression System® GS Ori-Go® Vectors GS piggyBac® Transposon System GS Xceed® Gene Expression System GSquad® Vectors Hot Melt Extrusion LNP Mammalian Expression Technologies Microbial Expression Technologies Micro-dosing/Powder-in-capsule Micronization Modified and Delayed Release Particle Size Reduction Spray Dried Dispersions Taste-masking and Multiparticulates Technology Selection Viral Vector Expression Technologies Xcite® XS Technologies®
Accelerating timelines Article Blog Brochure Career Opportunity CDMO Notes Blog post Conference Contact e-book Event Infographic Integration and agility Interview Location Media Advisory News Release Operational excellence Page Peer-reviewed publication Podcast Poster Presentation Presentation (on-demand) Presentation (slides) Process innovation Publication Quality and compliance (RA) R&D Blog post Report Technical/Service brief Tradeshow Video Webinar Webinar (on-demand) White paper
   Loading...
Showing 1‐28 of 634
Webinar (on-demand)
59 min read
Building Scalable Non-Viral Gene-Editing Cell Therapies
Achieving strong gene editing results is only the first step toward successful non-viral cell therapies. Long-term success depends on developing processes that consistently deliver high-quality cells, support scalability, and translate effectively into ma...
White paper
10 min read
in vivo CAR-T Strategic Market Update and Manufacturing Implications for CDMO Partners
In vivo CAR-T has become a strategic priority for large biopharma. Between 2025 and early 2026, the field saw a sequence of high-value acquisitions and platform deals involving AbbVie, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Kite, and Lilly-...
White paper
10 min read
Automated, Scalable, and GMP-compliant MSC Cell Therapy and EV Manufacturing Using Lonza TheraPEAK® MSC-VIVO™
Discover a practical approach to mesenchymal stem cell (MSC) and extracellular vesicle (EV) manufacturing that supports both process development and future commercial scale-up. This white paper explores how a xeno-free, GMP-grade culture medium ...
Technical/Service brief
3 min read
GS Gene Expression System® Brochure
The journey from discovery to commercial manufacturing demands expression technologies that deliver speed, performance, and confidence at every stage. Lonza's GS Gene Expression System® platform powers the development of biotherapeutic proteins with a com...
R&D Blog post
3 min read
A Decade of Determination: A Scientist’s Perspective on Advancing AAV Producer Cell Lines
Over the past decade, gene therapy has emerged as one of the most promising therapeutic modalities. Yet, unlocking its full potential depends on overcoming a central challenge: how to manufacture viral vectors at scale, consistently, and cost-effectively....
Webinar (on-demand)
35 min read
Simplifying ADC Development: An Integrated Path from Concept to Commercialization
As the Antibody-Drug Conjugate (ADC) market continues to expand, developers face increasing scientific, operational, and manufacturing complexity across the ADC lifecycle. Bringing these highly complex molecules from concept to commercialization requi...
CDMO Notes Blog post
10 min read
Making More from Every Bioreactor with Lonza’s OptiALTO® Intensified Fed-Batch Platform
Lonza’s OptiALTO® intensified fed-batch platform offers a practical way to increase productivity through higher titers, improved asset utilization, and more flexible supply strategies across the molecule lifecycle without compromising quality or scalabili...
Article
6 min read
Scaling Biologics with Early De-risking Package: Integrated Developability and Expression Q&A
Discover how integrated in silico tools, CHO expression, and in vitro immunogenicity testing help biotechs avoid costly technical and clinical hurdles.
Article
5 min read
De-risking Biologic Drug Development: Strategic Solutions for Biotech Companies
Biotech companies face unique challenges in developing increasingly complex biologic therapies. How can early de-risking, a smart chemistry, manufacturing and controls (CMC) strategy, and the right contract development and manufacturing organisation (CDMO...
Webinar (on-demand)
15 min read
Integrated ADC Offering: From Concept to Commercialization
Antibody-drug conjugates (ADCs) are transforming targeted therapies. However, their structural complexity makes selecting the right ADC CDMO partner critical to your clinical and commercial success. Lonza combines deep scientific expertise with fully integrated development and manufacturing capabilities. We support your ADC programs from early-stage development through to clinical and commercial supply. ...
Article
3 min read
Optimizing Lentiviral Vector Development For in vivo Delivery Of Cell and Gene Therapies
Challenges and emerging solutions in developing and manufacturing lentiviral vectors for in vivo cell and gene therapies
Article
1 min read
The IND Advantage: Why Early De-Risking Is a Strategic Imperative for Complex Biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that do not. In this article, Yvette ...
Blog
3 min read
Inhalable mRNA lipid nanoparticle powders via spray drying: is it possible?
Dry powder inhaled formulations of small molecule drugs are a mainstay of treatment for respiratory diseases such as asthma and COPD, and it’s a field where we have extensive experience here at Lonza
Webinar (on-demand)
55 min read
Cracking Complexity: Learnings from 70+ Bispecific Antibody Programs
The biologics pipeline is becoming increasingly complex as next generation antibody formats, including bispecific antibodies, move rapidly toward the clinic. For early stage biotech teams, this complexity often translates into uncertainty around where th...
Webinar (on-demand)
30 min read
Accelerating Success: Advanced Developability Strategies for Bioconjugates ​and ADCs
In this on-demand webinar, our experts explore how Lonza’s Early Development Services support the successful progression of bioconjugates—such as antibody–drug conjugates (ADCs)—from late discovery through early preclinical development. Discover how ...
Webinar (on-demand)
49 min read
The 24 Months Before CGT Launch
Every second counts: what real cell and gene therapy launches teach us For cell and gene therapies (CGTs), the path from a successful clinical readout to reliable commercial supply remains one of the most technically and operationally demanding trans...
Webinar (on-demand)
Faster Clones, Simpler Process: What’s Changing in CHO Expression?
This webinar will discuss the latest innovation in the GS® Expression System. We will discuss how Lonza’s advanced vector technology elevates protein expression performance through improved glutamine synthetase selection stringency combined with a high-st...
Peer-reviewed publication
20 min read
Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations
Antibody–drug conjugates (ADCs) combine the target specificity of monoclonal antibodies with the potency of cytotoxic small molecules, offering enhanced therapeutic potential. However, their inherent structural complexity, arising from the interplay of a...
Webinar (on-demand)
in vivo CAR-T And Gene Editing: The Manufacturing Reality Behind The Promise
In vivo CAR-T is moving fast, and so are the manufacturing challenges behind it. LNPs and viral vectors are both gaining ground as delivery platforms, but each comes with a distinct set of constraints that are already shaping which programs will scale an...
White paper
Avoiding the Pitfalls: Five Lessons for Cell Therapy Manufacturing Success
This white paper explores five common manufacturing and operational challenges that can delay or disrupt the transition from clinical development to commercial production in cell therapy. Designed for professionals involved in bringing cell therapy produc...
Article
7 min read
Expert Q&A: Navigating Complexity in Modern Small Molecule Development
Interview with our Lonza subject matter expert in small molecule development.
Webinar (on-demand)
55 min read
Early Developability Assessment for Antibody-based Therapeutics
In this on-demand webinar, Head of Immunology, Noel Smith, PhD, explores how our integrated toolbox — combining in silico screening, the GS® expression system, and human immune cell assays — supports early identification of developability and immunogenici...
Webinar (on-demand)
55 min read
From Insights to Impact: Predictive Models and PAT for More Efficient and Robust Biologics Manufacturing
Scaling biologics from development to commercial manufacturing requires precision, consistency, and control across both drug substance and drug product processes. Variability during scale-up—particularly in bioreactor operations and lyophilization—can i...
Poster
Advancing Lentiviral Genome Integrity and Titer Analysis Via Two Dimensional Reverse Transcription-digital PCR (2D RT-dPCR)
Lentiviral vectors (LVVs) are powerful and versatile gene‑transfer tools widely used in both ex vivo and in vivo cell and gene therapies. Traditional single‑channel dPCR or qPCR assay only provides limited information of the viral genome and cannot distin...
Poster
Establishment of a High‑Yield Stable Producer Cell Line for CD19 Chimeric Antigen Receptor-Based Lentiviral Vector Manufacturing
Lentiviral vectors (LVVs) are increasingly needed for gene and cell therapies, but transient transfection limits scalability and consistency. To address this need, we developed an inducible stable LVV producer cell line using a CD19 CAR as the gene‑of‑int...
Poster
A Robust System for High-titer, Platform-agnostic AAV Production in HEK293 Cell Lines
Successful Adeno-Associated Virus (AAV) programs requires careful choosing of critical production platform components such as engineered cell lines, plasmids and transfection reagents. Amongst them, cell culture medium being the environment of all upstream AAV production steps, is foundational to productivity and efficiency of packaging. Here we present a flexible cell culture media system that simplifies process development and optimization by demonstrating broad compatibility with commercially available AAV production components. This same system supports process development strategies that yield viral titers of >...
Poster
Accelerating Construction of AAV Stable Producer Cell Line with Integrated Process Development
AAV producer cell lines (PCLs) offer higher and consistent productivity, better scalability and process robustness, reduced cost of goods at scale compared to transient transfection based production. However, PCL adoption is often restrained by the extend...
Poster
Immunogenicity Risk Assessment of mRNA Therapeutics - Key Considerations When Assessing Preclinical Immunogenicity Risk
This poster highlights Lonza’s approach to preclinical immunogenicity risk assessment for mRNA/LNP therapeutics using human in vitro assays. Immunogenicity is influenced by multiple product‑ and process‑related factors, many of which can be evaluated earl...